key: cord-0986703-izuycqbz authors: Genecand, C.; Koegler, F.; Lebowitz, D.; Mongin, D.; Regard, S.; Nehme, M.; Braillard, O.; Grira, M.; Joubert, D.; Chopard, P.; Delaporte, E.; Stirnemann, J.; Guessous, I.; Tardin, A.; Courvoisier, D. S. title: Cohort profile: Actionable Register of Geneva Outpatients with SARS-CoV-2 (ARGOS) date: 2021-05-26 journal: nan DOI: 10.1101/2021.05.24.21256813 sha: 633de51bad7cc2bd28102c5ac42bef6e212436d0 doc_id: 986703 cord_uid: izuycqbz Purpose The Actionable Register of Geneva Outpatients with SARS-CoV-2 (ARGOS) is an ongoing prospective cohort created by the Geneva Directorate of Health (GDH). It consists of an operational database compiling all SARS-CoV-2 test results conducted in the Geneva area since late February 2020. While the disease evolution of patients hospitalized with SARS-CoV-2 are now relatively numerous, the same cannot be said for outpatients. This article aims at presenting a comprehensive outpatient cohort in light of the varying public health measures in Geneva, Switzerland, since March 2020. Participants As of July 28, 2020, the database included 58 226 patients, among which 6848 had at least one positive test result for SARS-CoV-2. Among all positive patients, 66.8% were contacted once, and 21% of participants had 3 or more follow-up calls. Participation rate is 96.9%. Data collection is ongoing. Findings to date ARGOS data illustrates the magnitude of COVID-19 pandemic in Geneva, Switzerland, and details a variety of population factors and outcomes. The content of the cohort includes demographic data, comorbidities and risk factors for poor clinical outcome, COVID-19 symptoms, environmental and socio-economic factors, contact tracing data, hospitalizations and deaths. Future plans: The data of this large real-world registry provides a valuable resource for various types of research, such as epidemiological research or policy assessment as it illustrates the impact of public health policies and overall disease burden of COVID-19. STRENGTHS AND LIMITATIONS OF THIS STUDY - ARGOS main strength consists of its large number of cases, representative of all diagnosed cases on a regional level with the primary aim of assessing all cases. - ARGOS involves every tested individual and is not limited to hospitalized patients, thus providing a valuable resource to assess the impact of public health policies and overall disease burden of COVID-19 in a geographically defined population. - To mitigate confounding effects and improve data analysis and interpretation, we present the data according to four policy periods. - This cohort is multicentric as it includes all tests performed in Geneva's hospitals (both public and private), private practices and medical centers. - Due to operational needs, symptoms and comorbidities are self-reported, which may lead to measurement error or misclassification. The data of this large real-world registry provides a valuable resource for various types of research, such as epidemiological research or policy assessment as it illustrates the impact of public health policies and overall disease burden of COVID-19. • ARGOS' main strength consists of its large number of cases, representative of all diagnosed cases on a regional level with the primary aim of assessing all cases. • ARGOS involves every tested individual and is not limited to hospitalized patients, thus providing a valuable resource to assess the impact of public health policies and overall disease burden of COVID-19 in a geographically defined population. • To mitigate confounding effects and improve data analysis and interpretation, we present the data according to four policy periods. • This cohort is multicentric as it includes all tests performed in Geneva's hospitals (both public and private), private practices and medical centers. • Due to operational needs, symptoms and comorbidities are self-reported, which may lead to measurement error or misclassification. Text word count: 2670 words . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. outbreak a global pandemic(1,2). As of July 29, 2020, the virus spread to 188 countries, infected close to 17 million people and caused 662 000 deaths(3,4). In Switzerland, the cumulative incidence of laboratory confirmed COVID-19 2 cases is one of the highest in Europe, with about 400 confirmed cases per 100'000 population at the end of July 2020(4,5) In the Geneva area, the first COVID-19 2 patient was diagnosed on February 26, 2020(6). Possibly due to the city's geographical proximity to Northern Italy(7), the epidemic curve showed a steep upward trend. The first wave of the epidemic peaked in Geneva on April 2nd with 233 cases in 24 hours in an area with a population of 500'000. Geneva's cumulative incidence of confirmed cases is almost 3 times that of Switzerland(5), with more than 1'000 cases per 100'000 population(6), while the seroprevalence was estimated to be close to 10 times that of the confirmed cases as 9.7% of the population had antibodies three weeks after the height of the epidemic(8,9). A database was created in early March in order to contact new cases and keep track of their follow-up. The Actionable Register of Geneva Outpatients with SARS-CoV-2 1 (ARGOS) includes all SARS-CoV-2 1 test results conducted in the Geneva area since late February 2020, as well as those from Geneva residents being tested in other Swiss cantons. The primary aim of this article is to present this comprehensive cohort, its 1 Severe acute respiratory syndrome coronavirus 2 2 coronavirus disease 2019 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2021. ; https://doi.org/10.1101/2021.05.24.21256813 doi: medRxiv preprint characteristics and the content of the data collected. The secondary aim is to interpret the data according to the public health measures implemented over time since the cohort profile was influenced by the varying policies enacted by the Swiss government and the Geneva State. The ARGOS database ARGOS is an ongoing prospective cohort created by the Geneva Directorate of Health (GDH) and consists of an operational database compiling all SARS-CoV-2 test results conducted in the Geneva area. Data are collected and managed using the REDCap electronic data capture tools(10,11) allowing the GDH to contact positive cases in order to promote public health measures and coordinate medical follow-up. It is set up as a collaborative tool between different institutions and medical entities, including the GDH, Geneva University Hospitals (HUG), and Geneva's main private medical centers. The latter have restricted access to data regarding their own patients only. The GDH and HUG are the only users to implement follow-up data in the electronic register. The data is hosted on HUG's secure servers. The register is administered by a committee of co-Principal Investigators belonging to the GDH and HUG, with the agreement of the cantonal ethic committee (CCER protocol 2020-01273). Participants in the database had the opportunity to refuse to participate in the registry, and those who did are excluded from the analyses presented here. The participation rate was 96.9%. Deidentified ARGOS data can be available upon reasonable request, including a research protocol, using the form. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 2020, did not get tested due to shortage of testing materials, unless they were healthcare workers, considered at-risk or hospitalized. However, symptomatic patients who visited the HUG COVID-19 testing center without fulfilling testing criteria were entered in the database as "suspected cases". Some of these patients later received a test as policy evolved on March 30, 2020. Patients or the public were not involved in research. What is being measured? . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2021. ; https://doi.org/10.1101/2021.05.24.21256813 doi: medRxiv preprint Unlike many countries which implemented near-complete lockdowns (19) and despite a high burden of confirmed cases, Switzerland decided to adopt less severe measures. On February 26, 2020, gatherings of more than 1000 people were prohibited in the country. The first two and a half weeks of the epidemic were characterized by a majority of positive tests among people aged 20 to 64 years-old (82.2%). Five percent of cases were above 80 years old, and all cases were experiencing acute symptoms. The main risk factors among infected patients were advanced age, with 15.4% being older than 65, followed by chronic respiratory disease, cardio-vascular disease and diabetes (5%, 4.6%, 2.9% respectively). During this period, the positivity rate was 9.5%. On the evening of March 13, 2020, the Swiss government and local authorities placed the country under partial lockdown. Border crossings were restricted to essential workers, schools were closed, workers were asked to work from home and only essential services remained open (20) . Public and private gatherings of more than 100 people and more than 5 people were banned on March 13, and March 20, 2020, respectively. From March 13 to March 29, 2020, SARS-CoV-2 reverse transcriptasepolymerase chain reaction testing was temporarily restricted to hospitalized and at-risk patients (>64 years old, presence of at least one risk factor for severe COVID-19, healthcare workers) due to shortage of testing materials. As patients receiving a test were selected based on their medical history and clinical course, we observed a first shift in the age of positive cases: the proportion of individuals 65 years and older, who are considered at risk for poor outcome, was higher (23.9%), and so was the presence of risk factors (chronic respiratory disease (11%), cardio-vascular disease (7.6%), . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2021. diabetes (5.3%) and immunosuppression (3.9%)). Individuals aged 20 to 39 years old were less represented during this period (28.5%). Healthcare workers were tested independently of their personal risk factors, and represented 12.2% of the positive patients. Limited testing modified the shape of the epidemic curve. It was concomitant with a sudden decrease of daily cases, mainly for younger people (Figure 1 ) and we witnessed a higher positivity rate (30.9%). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2021. ; https://doi.org/10.1101/2021.05.24.21256813 doi: medRxiv preprint regulations as well. The second step started on May 11, 2020 with the reopening of all shops, restaurants, and museums. Finally, on June 6, 2020, gatherings of less than 300 people were allowed, and nightclubs, cinemas, theaters and most schools reopened. The end of the lockdown measures was accompanied by the regulation of test prices in order to facilitate the access to free testing of symptomatic patients in Geneva. During this fourth phase, the cumulative number of cases reached a plateau. The proportion of patients with acute symptoms decreased significantly, reaching 86.5%. We observed a second shift in the age of positive cases, with 56.6% aged from 0 to 39 years, and only 10.8% older than 65 years old. 90.6% had no risk factor for severe disease. The positivity rate was 2.1%. One month after the beginning of the third step of containment release, we observed a new increase in daily cases, mainly affecting people from 20 to 39 years old, and leading to implementation of new public health policies. This ongoing phase of the epidemic will not be discussed in this article. COVID-19 represents a major challenge to each country's healthcare system. Collaboration between healthcare providers and public health authorities is particularly important in order to improve both our understanding of the disease and our response (22) (23) (24) . The publication of the ARGOS cohort underscores our willingness to share data for research purposes and for optimizing public health measures. Furthermore, analysis from the ARGOS database illustrates the impact of various testing policies on the proportion of risk factors or age groups identified among . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2021. ; https://doi.org/10.1101/2021.05.24.21256813 doi: medRxiv preprint children. Reasons to get tested have also evolved over the first months of the epidemic. For example, anosmia or ageusia became a testing criteria only in late April. Patients who presented with these isolated symptoms within the first two months of the epidemic could thus have been undertested. Seroprevalence study results confirm the underrepresentation of certain groups and the undertesting of the overall population (8). Nevertheless, ARGOS has several limitations. First, measurement error due to lack of detail of some variables can be observed, since efficiency was prioritized over detailoriented data collection. For instance, individuals' level of education is not recorded. Secondly, misclassification also certainly occurs as symptoms and risk factors are selfreported. Moreover, recording of information in ARGOS is performed by a large and evolving team of professionals, including healthcare workers with various backgrounds, medical students, or police recruits as of May 2020. Due to the crisis situation, training contents delivered to the GDH team often evolved, leading to a certain level of heterogeneity of phone interviews and a greater risk for misclassification of medical information. Thirdly, the patient information gathered is tailored to operational needs and growing scientific knowledge. For example, anosmia and ageusia were initially classified as general ENT symptoms, and were later detailed separately as they were recognized as frequent and specific manifestations of COVID-19 (25) . In conclusion, ARGOS is a large, real-world registry of individuals tested for SARS-Cov2 1 . Unlike many other registries, it involves every tested individual and is not limited to hospitalized patients, thus providing a precious resource to assess the impact of public health policies and overall disease burden of COVID-19. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2021. ; https://doi.org/10.1101/2021.05.24.21256813 doi: medRxiv preprint The publication of the ARGOS cohort underscores our willingness to share data for research purposes and for optimizing public health measures. Deidentified ARGOS data can be available upon reasonable request, including a research protocol, using the following form. The deindentified data underlying this article will be shared on reasonable request to the corresponding author, using the form (https://edc.hcuge.ch/surveys/?s=TLT9EHE93C) Research received the agreement of the Cantonal Ethic Committee of Geneva (CCER protocol 2020-01273). National Science Foundation LIVES, project #2020-01273. We thank all members of the COVID-19 team at the General Directorate of Health, as well as all healthcare providers and laboratories involved in the management of COVID-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2021. ; https://doi.org/10.1101/2021.05.24.21256813 doi: medRxiv preprint 19 patients. We also wish to thank all patients and their contacts who are included in the ARGOS database. The authors declare no conflict of interest. Each author contributed to this article, based on the criteria of the International . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2021. ; https://doi.org/10.1101/2021.05.24.21256813 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Red Flags − New-onset or worsening dyspnea − Fever for more than 5 days, or worsening fever non responding to treatment − Deterioration of the general status . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2021. ; https://doi.org/10.1101/2021.05.24.21256813 doi: medRxiv preprint Clinical Characteristics of Coronavirus Disease 2019 in China Clinical features of covid-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Crosssectional Study Covid-19: a remote assessment in primary care Rapid risk assessment: Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK -eighth update Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China Conseil fédéral renforce les mesures contre le coronavirus pour protéger la santé de la population et soutient les secteurs touchés Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study Successful Elimination of Covid-19 Transmission in New Zealand Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study ) 223 (28.1) 2.1) 496 (18.5)